With gonorrhea's rising antibiotic resistance, Recce 327 by Recce Pharmaceuticals emerges as a game-changer, showing 99% efficacy in preclinical trials and promising potential against antibiotic-resistant bacteria globally.
James Graham, CEO of Recce Pharmaceuticals
Advertisement
Articles by James Graham, CEO of Recce Pharmaceuticals
Advertisement
Latest Updated Articles
Infection Prevention Connection: An IPC Crossword ChallengePublished: August 11th 2025 | Updated: August 13th 2025
Championing Surgical Safety: A Perioperative Nurse’s Perspective on Infection PreventionPublished: July 22nd 2025 | Updated: July 23rd 2025
Alcohol-Based Hand Sanitizers Ineffective Against Norovirus: Effective Alternatives and Infection Control StrategiesPublished: May 30th 2024 | Updated: January 7th 2025
Norovirus: An Old Virus Seeking New Public Health ActionsPublished: May 3rd 2024 | Updated: January 6th 2025
Meet Infection Control Today's Editorial Board Member: Tabrikah Mohammed, MSc, BSN, CIC, CPHQ, FAPICPublished: March 5th 2024 | Updated: August 6th 2024
Targeting Uncertainty: Why Pregnancy May Be the Best Time to Build Vaccine ConfidencePublished: July 15th 2025 | Updated:
Advertisement
Advertisement
